What is the Aarti Drugs PE ratio today?
Aarti Drugs' PE ratio is 21.4 at the 29 October 2026 close (₹449.00 a share): a market capitalisation of ₹4,098 crore divided by consolidated net profit of ₹191 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹195 crore) it is 21.0.
What is the Aarti Drugs net worth?
Aarti Drugs' net worth — shareholders' equity in its consolidated balance sheet — was ₹1,549 crore on 31 March 2026, up 13.1% from ₹1,369 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹4,098 crore at the 29 October 2026 close.
What is the Aarti Drugs book value per share?
Aarti Drugs' book value per share was ₹169.70 on 31 March 2026: shareholders' equity of ₹1,549 crore divided by the 9.13 crore shares in issue, up 13.1% from ₹149.99 a year earlier. The share price at the 29 October 2026 close was ₹449.00.
What is the Aarti Drugs PB ratio (price to book value)?
Aarti Drugs' price-to-book (PB) ratio is 2.65 at the 29 October 2026 close: a market capitalisation of ₹4,098 crore divided by shareholders' equity (book value) of ₹1,549 crore on 31 March 2026. That is a book value of ₹169.70 per share against a share price of ₹449.00.
What is the Aarti Drugs ROE and ROCE?
In FY26, Aarti Drugs' return on equity (ROE) was 13.4% and its return on capital employed (ROCE) was 13.3%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 12.7% and ROCE 13.7%.
What is the Aarti Drugs dividend yield?
Aarti Drugs' dividend yield is 0.45% at the 29 October 2026 close: dividends of ₹2 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹449.00. They were ₹2 on 9 February 2026 (interim).
What is the Aarti Drugs market cap?
Aarti Drugs' market capitalisation was ₹4,098 crore at the 29 October 2026 close: 9.13 crore shares at ₹449.00 each.
What is the Aarti Drugs EPS?
Aarti Drugs' basic earnings per share (EPS) were ₹21.36 in FY26, against ₹18.35 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹20.93.
What is the Aarti Drugs dividend in 2026 and its record date?
In 2026, Aarti Drugs has declared one dividend: ₹2 (interim) with record date 9 February 2026.
Is Aarti Drugs debt free?
No. Aarti Drugs had borrowings of ₹575 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.37. Its cash and current investments were ₹8.8 crore, so its net debt was ₹566 crore.
What is the Aarti Drugs debt to equity ratio?
Aarti Drugs' debt-to-equity ratio was 0.37 on 31 March 2026: borrowings of ₹575 crore against total equity of ₹1,549 crore. A year earlier, on 31 March 2025, it was 0.45.
What is the Aarti Drugs promoter holding?
Promoters held 54.07% of Aarti Drugs on 30 September 2026, down 0.36 percentage points from 54.43% the previous quarter and down 0.65 percentage points from 54.72% a year earlier, according to the shareholding pattern filed with NSE.
What is the Aarti Drugs shareholding pattern?
On 30 September 2026, Aarti Drugs' shares were held by promoters 54.07%, foreign portfolio investors (FII/FPI) 2.26%, domestic institutions (DII) 10.24% (including mutual funds at 9.97%) and retail and other non-institutional investors 33.43%. Over the year, FII holding was down 0.43 percentage points from 2.69% and DII holding was up 0.34 percentage points from 9.90%.
What is the Aarti Drugs revenue and profit in FY26?
In FY26 (April 2025–March 2026), Aarti Drugs' consolidated net profit was ₹195 crore, up 15.9% from ₹168 crore in FY25, on revenue from operations of ₹2,565 crore (up 7.5%). Over three years, from FY23, net profit was up 17.2%.
How does the Aarti Drugs PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Aarti Drugs' PE ratio is 21.0, the second highest of the three: Aarti Pharmalabs 48.7 and Advanced Enzyme Tech 17.5, a peer average of 33.1. Each is the company's market capitalisation at that price divided by its FY26 net profit.
What is the Aarti Drugs free cash flow?
In FY26, Aarti Drugs generated ₹254 crore of cash from operations and spent ₹173 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹80.2 crore. In FY25 it was ₹67.4 crore.
What are the Aarti Drugs latest quarterly results?
Aarti Drugs' latest results are for Q1 FY27 (April–June 2026), filed on 31 July 2026: consolidated net profit ₹50.2 crore, down 6.9% from ₹53.9 crore in Q1 FY26; revenue from operations ₹703 crore, up 19.0% year on year.
When are the Aarti Drugs next results?
Aarti Drugs will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, the date of the board meeting it has notified to the exchanges.
How does Aarti Drugs compare with its peers?
On FY26 consolidated figures, against Aarti Pharmalabs and Advanced Enzyme Tech: Aarti Drugs' operating margin of 9.4% is the lowest of the three (Aarti Pharmalabs 14.6%, Advanced Enzyme Tech 25.3%; peer average 20.0%); its return on equity of 13.4% is the highest of the three (Aarti Pharmalabs 8.4%, Advanced Enzyme Tech 11.1%; peer average 9.7%); its revenue growth over three years of −1.9% a year is the second highest of the three (Aarti Pharmalabs −2.2% a year, Advanced Enzyme Tech 11.3% a year; peer average 4.6% a year).
Aarti Drugs vs Aarti Pharmalabs: how do they compare?
In FY26, Aarti Drugs earned net profit of ₹195 crore on revenue of ₹2,565 crore, against ₹173 crore on ₹1,819 crore for Aarti Pharmalabs. Aarti Drugs' operating margin was 9.4% (Aarti Pharmalabs 14.6%) and its return on equity 13.4% (Aarti Pharmalabs 8.4%). At the 29 October 2026 close, Aarti Drugs' market capitalisation was ₹4,098 crore against ₹8,412 crore for Aarti Pharmalabs, and its PE ratio on FY26 profit 21.0 against 48.7.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
